Navigation Links
Increasing dosage of clopidogrel for patients with genetic variation improves response to medication
Date:11/16/2011

CHICAGO Among patients with stable cardiovascular disease who have a genetic variation that diminishes the response to the antiplatelet drug clopidogrel, tripling the standard daily dosage of this medication resulted in improved platelet reactivity, according to a study appearing in JAMA. The study is being released early online to coincide with its presentation at the American Heart Association Scientific Sessions.

"Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel," according to background information in the article. Variability in the pharmacodynamic response to clopidogrel is well recognized, and patients with higher platelet reactivity while receiving clopidogrel are at increased risk of adverse cardiovascular events. " data are needed to offer guidance as to what might constitute optimal treatment strategies in patients with loss-of-function CYP2C19 alleles [an alternative form of a gene]."

Jessica L. Mega, M.D., M.P.H., and Marc S. Sabatine, M.D., M.P.H., of Brigham and Women's Hospital and Harvard Medical School, Boston, and colleagues conducted a multicenter, randomized trial to test whether maintenance doses of up to 300 mg daily of clopidogrel can improve platelet reactivity in the setting of loss-of-function CYP2C19 genotypes, particularly among heterozygotes (a person possessing one copy of a variant gene), who constitute approximately 25 percent to 45 percent of the population, depending on racial background. The trial (ELEVATE-TIMI 56) enrolled and genotyped 333 patients with cardiovascular disease across 32 sites from October 2010 until September 2011.

Patients received maintenance doses of clopidogrel for 4 treatment periods, each lasting approximately 14 days, based on genotype. In total, 247 noncarriers of a CYP2C19*2 loss-of-function allele were randomized to receive 75 and 150 mg daily of clopidogrel (2 periods each), whereas 86 carriers (80 heterozygotes, 6 homozygotes [having two copies of the variant gene]) were randomized to receive 75, 150, 225, and 300 mg daily. Two methods were used to measure platelet function. The average age of the patients was 60 years, 75 percent were male, 57 percent had a history of heart attack, and 97 percent had a history of percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries).

Among the main findings of the researchers was that higher maintenance doses of clopidogrel in patients carrying a CYP2C19*2 allele significantly reduced platelet reactivity. Also, daily maintenance doses of 225 mg of clopidogrel or greater in CYP2C19*2 heterozygotes improved platelet reactivity levels that were at least equivalent to what is achieved with 75 mg daily of clopidogrel in noncarrier patients with cardiovascular disease. When evaluating the CYP2C19*2 homozygotes, the researchers saw a trend toward less platelet reactivity with higher maintenance doses of clopidogrel; however, even with 300 mg daily of clopidogrel, these individuals were unlikely to achieve optimal degrees of platelet inhibition.

"These data help define how patients with different CYP2C19 genotypes respond to clopidogrel maintenance dosing strategies and provides useful information to guide further clinical studies," the authors conclude.


'/>"/>

Contact: Marjorie Montemayor-Quellenberg
quellenberg@partners.org
617-534-2208
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. NYUCN receives $994,000 HRSA grant to research increasing nursing faculty diversity
2. Study finds liver cancer increasing in low risk countries, decreasing in high risk countries
3. Local efforts can stem the increasing unnecessary cesarean sections
4. Vascular disease management increasingly important
5. Researchers find increasing the number of family physicians reduces hospital readmissions
6. Success of First World Congress of Pediatric Urology underscores increasing importance of specialty
7. UNC study finds oral tongue cancer increasing in young, white females
8. Income inequalities are increasing the occurence of depression during financial crisis
9. Increasingly, Other Ailments Prove Fatal for People With COPD
10. Hospice care increasing for nursing home patients with dementia
11. Influenza virus strains show increasing drug resistance and ability to spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Austin, TX (PRWEB) , ... December 05, 2016 ... ... Center for Facial Plastic Surgery, is excited to announce the arrival of the ... hybrid fractional laser, with the ability to use tunable non-ablative and ablative wavelengths ...
(Date:12/5/2016)... ... , ... Researchers at Johns Hopkins All Children’s Hospital want to learn more ... course of three years, researchers will study concussions and changes in brain function by ... special sensors, will track the location and force of the hit. The sensors store ...
(Date:12/5/2016)... Nashville, Tennessee (PRWEB) , ... ... ... leader in strategic interoperability, today announced that the company will provide alerting ... platform. CIHIE has been recently awarded $1.7 million in federal funds as ...
(Date:12/5/2016)... ... ... Sideline Products is a Southern York County Pennsylvania-based premier designer and manufacturer founded ... Smaller saddles can pinch and irritate the horse creating safety issues and limiting comfort ... saddle so it does not impact the comfort or performance of the horse. Further, ...
(Date:12/5/2016)... ... 05, 2016 , ... The legislation – S2718A/A2116A ... a licensed physical therapist, to render care for certain patients. In most cases, ... a licensed physical therapist (PT) and throughout the treatment cycle is supported by ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LAS VEGAS , Dec. 5, 2016  BD ... a leading global medical technology company, will demonstrate an ... BD medication management technologies, including the company,s leading Pyxis™ ... of Health-System Pharmacists (ASHP) 2016 Midyear Meeting being ... Dec. 4-8. While national data show that ...
(Date:12/5/2016)... Dec 5, 2016 Research and Markets has announced ... Global Forecast to 2021" report to their offering. ... , , The ... billion by 2021, at a CAGR of 5.3% from 2016 to 2021. ... of obesity cases, increasing government spending on healthcare, and rising income levels ...
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
Breaking Medicine Technology: